Avoiding surgery in prostate cancer patients with low-risk disease

Therapy

Volumn 5, Issue 1, 2008, Pages 25-36

  Mouraviev, Vladimir ^a   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cryoablation; Focal therapy; HIFU; Photodynamic therapy; Prostate cancer

Indexed keywords

PALLADIUM BACTERIOPHEOPHORBIDE; PROSTATE SPECIFIC ANTIGEN; TETRAKIS(3 HYDROXYPHENYL)CHLORIN;

ANTIGEN DETECTION; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED THERAPY; CONTRAST ENHANCEMENT; CRYOABLATION; CRYOSURGERY; CRYOTHERAPY; DISEASE FREE SURVIVAL; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; IMPOTENCE; NEEDLE BIOPSY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE PLANNING; PATIENT MONITORING; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RECTUM FISTULA; REFERENCE VALUE; RISK ASSESSMENT; STRESS INCONTINENCE; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; TREATMENT INDICATION; URETHRA FISTULA; URINARY TRACT INFECTION;

EID: 38349115030     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.1.25     Document Type: Article

References (56)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carron PR: The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 22, 2141-2149 (2004).
2. Cooperberg MR, Moul JW, Carron PR: The changing face of prostate cancer. J. Clin. Oncol. 23, 8146-8151 (2005).
3. Mouraviev V, Polascik TJ: Update on cryotherapy for prostate cancer in 2006. Curr. Opin. Urol. 16, 152-156 (2006).
4. Rukstalis D: Focal cryoabiation of the prostate: patient-specific modifications of ultrasound guided-prostatic cryoablation. In: Handbook of uralogic cryoablation. Rukstalis DB, Katz A (Eds). Informa Healthcare, NY 10016, USA, 57-66 (2007).
5. Johansson JE: Watchful waiting for early stage prostate cancer. Urology 43, 138-142 (1994).
6. Bill-Axelson A, Holmberg L, Ruutu M et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977-1984 (2005).
7. Johansson JE, Andren O, Andersson SO et al.: Natural history of early, localized prostate cancer. JAMA 291, 2713-2719 (2004).
8. Albertsen PC, Hanley A Penson DF. Barrows G, Fine J: 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J. Urol. 177, 932-936 (2007).
9. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 21, 2163-2172 (2003).
10. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J. Urol. 167, 1231-1234 (2002).
11. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J. Urol. 171, 1520-1524 (2004).
12. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol. Oncol. 24, 46-50 (2006).
13. Carter HB, Kettermann A, Warlick C et al.: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins Experience. J. Urol. 178(6), 2359-2364; discussion 2364-2365 (2007).
14. Klotz L: Active surveillance for genitourinary cancer: an overview. Urol. Oncol. 24, 44-45 (2006).
15. Nakanishi H, Wang X, Ochiai A et al.: A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer. 110(11), 2441-2447 (2007).
16. Onik G: Rationale for a 'male lumpectomy,' a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovasc. Intervent. Radiol. (2007) (Epub ahead of print).
17. Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC: Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 60, 12-18 (2002).
18. Onik G, Narayan P, Vaughan D. Dineen M, Brunelle R: Focal 'nerve-sparing' cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 60, 109-114 (2002).
19. Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ: Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol. Cancer Res. Treat. 6, 91-96 (2007).
20. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 110, 906-910 (2007).
21. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ: Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology 71 (2007) (In press).
22. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO: Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod. Pathol. 18, 1022-1026 (2005).
23. Ohori M, Eastham JA, Koh H et al.: Is focal therapy reasonable in patients with early stage prostate cancer (CAP) - an analysis of radical prostatectomy (RP) specimens. J. Urol. 175(Suppl.), 507 (Abstract 1574) (2006).
24. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU: Prostate cryoablation: a scientific rationale for future modifications. Urology 60, 19-25 (2002).
25. Onik G: The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. lechnol. Cancer Res. Treat. 3, 365-370 (2004).
26. Haider MA, Davidson SR. Kale AV et al.: Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology. 244, 196-204 (2007).
27. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J. Urol. 176, 2432-2437 (2006).
28. Rouviere O. Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D: Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur. J. Radiol. 63, 317-327 (2007).
29. Nakashima J, Tanimoto A, Imai Y et al.: Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 64, 101-105 (2004).
30. Barzell WE, Carey RI, Melamed MR: The utility of transperineal 3-dimensional pathological mapping in counseling patients seeking expectant management for low volume prostate cancer. Presented at: Seventh Annual Society of Urologic Oncology meeting. Bethesda, MD, USA, 30 November-2 December, Abstract book 91 (2006).
31. Galosi AB, Lugnani F, Muzzonigro G: Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. J. Endourol. 21, 1-7 (2007).
32. Han KR, Cohen JK, Miller RJ et al.: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J. Urol. 170, 1126-1130 (2003).
33. Miller R, Cohen J: Prostate Cryosurgery. In: Handbook of urologic cryoablation. Rukstalis DB. Katz A (Eds). Informa Healthcare, NY 10016, USA, 39-46 (2007).
34. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D: Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int. 97, 969-974 (2006).
35. Han KR. Belldegrun AS: Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 93, 14-18 (2004).
36. Prepelica KL, Okeke Z, Murphy A, Katz AE: Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 103, 1625-1630 (2005).
37. Polascik TJ, Nosnik I, Mayes JM, Mouraviev V: Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology 70, 117-121 (2007).
38. D'Amico AV: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park, AM) 15, 1049-1059; discussion 1060-1042, 1064-1045, 1069-1070, 1073-1045 (2001).
39. Janzen NK, Han KR, Perry KT, Said JW, Schulam PG, Belldegrun AS: Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J. Endourol. 19, 520-525 (2005).
40. Lambert EH, Bolte K, Masson P, Katz AE: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69, 1117-1120 (2007).
41. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC: Focal prostate cryoablation: initial results show cancer control and potency preservation. J. Endoural. 20, 688-692 (2006).
42. Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr. Urol. Rep. 4, 248-252 (2003).
43. Blana A. Walter B. Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63, 297-300 (2004).
44. Thueroff S KK, Chaussy C: 10 years,high intensity focused ultrasound (HIFU) as local treatment of prostate cancer: profile of side effect. J. Urol. 175(Suppl.), 364 (2006).
45. Uchida T, Sanghvi NT. Gardner TA et al.: Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology 59, 394-398; discussion 398-399 (2002).
46. Poissonnier L, Chapelon JY, Rouviere O et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur. Urol. 51, 381-387 (2007).
47. Murat FJ, Poissonnier L, Pasticier G, belet A: High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control 14, 244-249 (2007).
48. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 55, 3346-3351 (1995).
49. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J: Photodynamic therapy for urological malignancies: past to current approaches. J. Urol. 175, 1201-1207 (2006).
50. Weersink RA, Bogaards A, Gertner M et al.: Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J. Pbotochem. Photobiol. B Biol. 79, 211-222 (2005).
51. Huang Z, Chen Q, Luck D et al.: Studies of a vascular-acting photosensitizer, Pd bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer. Lasers Surg. Med. 36, 390-397 (2005).
52. Epstein JI, Chan DW, Sokoll LJ et al.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J. Urol. 160, 2407-2411 (1998).
53. Gardner TA, Lerner ML, Schlegel PN, Waldbaum RS, Vaughan ED Jr, Steckel J: Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume. Br. J. Urol. 81, 839-843 (1998).
54. Terris MK, McNeal JE, Stamey TA: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol. 148, 829-832 (1992).
55. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur. Urol. 48, 895-899 (2005).
56. Noguchi M, Stamey TA, McNeal JE, Yemoto CM: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J. Urol. 166, 104-109 (2001).